CD4+, CD8+ and lymphocyte counts (mean [+ or -] SD) of patients according to their HTLV serology Laboratory HTLV serology Values/clinical Negative Status n 102 Symptomatic 50 CD4 cell counts 25 140 [+ or -] 177 CD8 cell
counts 25 695 [+ or -] 403 Lymphocytes 50 887 [+ or -] 515 Asymptomatic * 73 CD4 cell counts 50 434 [+ or -] 281 CD8 cell
counts 50 1,300 [+ or -] 883 Absolute lymphocyte count 72 2,013 [+ or -] 912 All patients 123 CD4 cell counts 75 334 [+ or -] 284 CD8 cell
counts 75 1,112 [+ or -] 813 Absolute lymphocyte count 123 1,563 [+ or -] 952 Laboratory HTLV serology Values/clinical HTLV-I HTLV-II Status 25 0.
A small case-control study determined that aging HIV-infected people (median 56 years) with a good CD4 count (median 724 cells/mm (3)) and long-term viral suppression with antiretroviral therapy have CD4 and CD8 cells
similar to those of a substantially older HIV-negative comparison group (median 88 years) and utterly unlike those of a younger HIV-negative group (median 27 years).
Both groups had similar concentrations of CD8 cells
The proportion of CD4 cells normally exceeds that of CD8 cells
But in the US study, the CD8 cells
suppressed the virus without killing the healthy CD4T cells.
Overall, they found that the telomere length of CD8 cells
was significantly shorter than CD4 telomere length in a group of 14 HIV-infected men, suggesting the new CD8 cells
were being produced much faster than CD4 cells.
According to our results patients with more severe form of disease had the lowest number of both CD4 and CD8 cells
which can be a sign of suppressed cellular immunity in these patients.
The researchers also used a new test for HIV-specific immune function--counting the proportion of virus-specific CD8 cells
by using flow cytometry to measure which of the cells produce gamma interferon in response to killed virus.
Cloyd says that this finding could explain why the number of CD8 cells
does not dramatically decline during HIV infection.
The new study concluded that the human immunodeficiency virus prompts CD8 cells
to replicate at such a fast rate that eventually they grow too old to replicate themselves, the study found.
The results of these recent assessments, presented for the first time at the International AIDS Conference in Mexico, show that this novel product induces greater proliferation, maturation and differentiation of HIV-specific CD8 cells
They found that the original portions of the virus degrade 400 times faster in response to CD8 cells
than they would have if those cells weren't a factor - what scientists call significant "selective pressure" on the virus.